宜明昂科成功配售3315万股 融资约2.3亿港元
财中社11月28日电宜明昂科-B（01541）发布公告，宣布根据配售协议的条款，已于2024年11月28日成功交割，完成新H股的配售。此次配售共计3315万股，配售价为每股7.05港元，交割前占公司已发行股本的约8.86%及已发行H股总数的约9.50%。交割后，公司的已发行股份总数由3.74亿股增至4.07亿股，已发行H股总数由3.49亿股增至3.82亿股。
此次配售所得款项净额约为2.3亿元，净配售价约为每股6.93港元。资金用途包括约30%用于在中国进行IMM2510联合化疗一线治疗非小细胞肺癌和三阴性乳腺癌的临床研究，约30%用于IMM2510联合IMM27M治疗晚期实体瘤的研究，约10%用于IMM01与阿扎胞苷及替雷利珠单抗联合疗法的关键性临床研究，剩余约30%将补充公司运营资金。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10